Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Bone as a Preferential Site for Metastasis.

Sowder ME, Johnson RW.

JBMR Plus. 2019 Jan 15;3(3):e10126. doi: 10.1002/jbm4.10126. eCollection 2019 Mar. Review.

2.

Bone Metastasis: Find Your Niche and Fit in.

Zhang W, Bado I, Wang H, Lo HC, Zhang XH.

Trends Cancer. 2019 Feb;5(2):95-110. doi: 10.1016/j.trecan.2018.12.004. Epub 2019 Jan 17. Review.

PMID:
30755309
3.

Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities.

Byrne NM, Summers MA, McDonald MM.

JBMR Plus. 2019 Jan 7;3(3):e10125. doi: 10.1002/jbm4.10125. eCollection 2019 Mar. Review.

4.

Bone metastasis and the metastatic niche.

Ren G, Esposito M, Kang Y.

J Mol Med (Berl). 2015 Nov;93(11):1203-12. doi: 10.1007/s00109-015-1329-4. Epub 2015 Aug 15. Review.

5.

Targeting tumor-stromal interactions in bone metastasis.

Esposito M, Kang Y.

Pharmacol Ther. 2014 Feb;141(2):222-33. doi: 10.1016/j.pharmthera.2013.10.006. Epub 2013 Oct 15. Review.

6.

AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, DeMarzo AM, Pienta KJ.

Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5.

PMID:
30291220
7.

The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.

Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, McGee S, Lee E, Nagrath S, Pienta KJ, Taichman RS.

Oncotarget. 2016 Jul 5;7(27):41217-41232. doi: 10.18632/oncotarget.9251. Erratum in: Oncotarget. 2017 Jun 6;8(23 ):38075.

8.

Microenvironments dictating tumor cell dormancy.

Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA.

Recent Results Cancer Res. 2012;195:25-39. doi: 10.1007/978-3-642-28160-0_3. Review.

9.

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

Chung LW, Baseman A, Assikis V, Zhau HE.

J Urol. 2005 Jan;173(1):10-20. Review.

PMID:
15592017
10.

The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis.

Roato I, Vitale M.

Front Endocrinol (Lausanne). 2019 Mar 7;10:145. doi: 10.3389/fendo.2019.00145. eCollection 2019. Review.

11.

Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH.

Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7.

PMID:
29514796
12.

The Biology of Bone Metastasis.

Esposito M, Guise T, Kang Y.

Cold Spring Harb Perspect Med. 2018 Jun 1;8(6). pii: a031252. doi: 10.1101/cshperspect.a031252. Review.

13.

Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.

Quayle L, Ottewell PD, Holen I.

Curr Cancer Drug Targets. 2015;15(6):469-80. Review.

PMID:
25968899
14.

Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?

Farach-Carson MC, Lin SH, Nalty T, Satcher RL.

Front Oncol. 2017 Aug 7;7:163. doi: 10.3389/fonc.2017.00163. eCollection 2017. Review.

15.

Mechanisms of Metastatic Tumor Dormancy.

Osisami M, Keller ET.

J Clin Med. 2013 Sep 23;2(3):136-50. doi: 10.3390/jcm2030136. Review.

16.

The role of hematopoietic stem cell niche in prostate cancer bone metastasis.

Decker AM, Jung Y, Cackowski F, Taichman RS.

J Bone Oncol. 2016 Feb 19;5(3):117-120. eCollection 2016 Sep.

17.

Tumor cell dormancy.

Gomis RR, Gawrzak S.

Mol Oncol. 2017 Jan;11(1):62-78. doi: 10.1016/j.molonc.2016.09.009. Epub 2016 Oct 7. Review.

18.

The Relationship Between Dormant Cancer Cells and Their Microenvironment.

Linde N, Fluegen G, Aguirre-Ghiso JA.

Adv Cancer Res. 2016;132:45-71. doi: 10.1016/bs.acr.2016.07.002. Epub 2016 Aug 25. Review.

19.

Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone.

Marsden CG, Wright MJ, Carrier L, Moroz K, Rowan BG.

PLoS One. 2012;7(11):e47587. doi: 10.1371/journal.pone.0047587. Epub 2012 Nov 15.

20.

Understanding the Bone in Cancer Metastasis.

Fornetti J, Welm AL, Stewart SA.

J Bone Miner Res. 2018 Dec;33(12):2099-2113. doi: 10.1002/jbmr.3618. Epub 2018 Nov 26. Review.

PMID:
30476357

Supplemental Content

Support Center